<DOC>
	<DOCNO>NCT00815568</DOCNO>
	<brief_summary>The purpose study evaluate OS , RFS , TRM HCT low-dose total body irradiation , fludarabine , busulfan conditioning .</brief_summary>
	<brief_title>Feasibility Efficacy Study Conditioning Regimen Allogeneic Hematopoietic Cell Transplantation ( HCT ) With Fludarabine , Busulfan , Total Body Irradiation ( TBI )</brief_title>
	<detailed_description>Conventional allogeneic hematopoietic cell transplantation ( HCT ) patient hematological malignancy involve condition high dos systemic chemo/radiation therapy cyclophosphamide ( CY ) plus 1200 1000 cGy total body irradiation ( TBI ; CY/TBI ) busulfan ( Bu ) / CY ( BuCy ) . Unfortunately , regimen associate significant toxicity , limit use otherwise healthy , relatively young patient . Recently , Fludarabine plus 4 day dose busulfan ( FluBu4 ) contain myeloablative regimen introduce successfully without increase transplant-related mortality ( TRM ) . To improve transplant outcome without increase risk recurrence , Russell et al introduce 400cGy TBI antithymocyte ( ATG , 4.5mg/Kg ) FluBu4 regimen successful outcomes .</detailed_description>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>At least 15 year old 65 year old . ECOG performance status 02 . Patients AML MDS intermediate/unfavorable cytogenetics . Patients ALL CML ineligible Cy/TBI conditioning . Patients NHL HD eligible myeloablative HCT . Patients receive unrelated BMT AML , MDS , ALL , CML , NHL HD . Consent form sign date prior study specific procedure . Subject able comply schedule followup management toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>fludarabine</keyword>
	<keyword>busulfan</keyword>
	<keyword>total body irradiation</keyword>
	<keyword>condition regimen</keyword>
</DOC>